Pulmonary alveolar proteinosis clinico-Pathologic conferences

Current estimates place its incidence in the United States at approximately one in 300,000 (3). Men are more commonly affected, with a median age of diagnosis of approximately 40 years and 70% of patients have a history of smoking (1). alveolar proteinosis. Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impair-ment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are pre-dominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the under- standing of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor anti- bodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing aware- ness among physicians when treating patients who present with alveolar infiltrates. congénitale,

On laboratory evaluation, the patient's comprehensive metabolic panel and complete blood count with differential were within normal limits. Arterial blood gas analysis on room air revealed a pH of 7.47, PCO 2 31.5 mmHg, PO 2 43.3 mmHg and HCO 3 -23 mEq/L. Pulmonary function testing demonstrated normal spirometry with decreased diffusion capacity for carbon monoxide (DLCO 34% of predicted). A chest x-ray revealed new diffuse bilateral alveolar infiltrates without other abnormalities. Additional laboratory testing revealed an elevated C-reactive protein level (719 nmol/L [75.5 mg/L]); however, antinuclear antibody, rheumatoid factor, an antineutrophil cytoplasmic antibody panel and immunoglobulin levels returned normal. The patient underwent high-resolution computed tomography (HRCT) of the chest, which demonstrated centrilobular emphysema and ground-glass opacities with superimposed interlobular septal thickening.
The patient underwent bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsies. There were no endobronchial abnormalities. BAL microbiology was negative, including opportunistic infections such as Pneumocystis and Nocardia. Cytology was normal. There were no significant hemosiderin-laden macrophages. Transbronchial biopsies showed chronic inflammation, thickened interlobular septae and alveolar acellular material that was negative for Grocott's methanamine silver (GMS) stain (Figures 1 and 2). Given the clinical and pathological findings, a diagnosis of pulmonary alveolar proteinosis (PAP) was made.

DISCUSSION
First reported in 1958, PAP is characterized by the accumulation of phospholipoproteinaceous material within the alveoli as a result of decreased protein clearance by pulmonary macrophages (1,2). Current estimates place its incidence in the United States at approximately one in 300,000 (3). Men are more commonly affected, with a median age of diagnosis of approximately 40 years and 70% of patients have a history of smoking (1). Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates. There are three forms of PAP: congenital, acquired and idiopathic; of which the latter two are predominant in the adult population. Previous case studies have found that the acquired form can be secondary to various autoimmune, infectious, malignant and environmental etiologies. Recent advances in the understanding of the pathophysiology of PAP demonstrate that the idiopathic form is due to antigranulocyte macrophage-colony stimulating factor antibodies. Therapeutic targets that replace granulocyte macrophage colony stimulating factor or remove these antibodies are being actively developed. The current standard of care is to perform whole lung lavage on these patients to clear the alveolar space to help improve respiratory physiology. A case of PAP is reported, followed by a literature review on the diagnosis and management of this rare condition with the aim of increasing awareness among physicians when treating patients who present with alveolar infiltrates.
There are three forms of PAP: congenital, acquired and idiopathic ( Figure 3) (4). Congenital PAP usually presents as neonatal respiratory distress syndrome. It is believed to result from mutations/deficiencies in surfactant proteins or the granulocyte macrophage-colony stimulating factor (GM-CSF) receptor. Acquired PAP typically presents during adulthood and is associated with abnormal alveolar macrophage function due to malignancies, infections, systemic inflammatory disorders, immunosuppression or toxic exposures (Table 1) (1). Finally, idiopathic PAP is the most common form (>90%) in adults, and is believed to be due to anti-GM-CSF antibodies that inhibit alveolar macrophage function. These categories must be taken with a caveat because there is a growing body of literature to indicate that there may be an overlap between what is referred to as idiopathic and acquired PAP. For instance, various reports have demonstrated that patients with a previous exposure have also shown positive titres for GM-CSF antibodies, while those with positive antibodies have retrospectively been identified as having typical exposures that were characteristic of acquired PAP (5,6).
The main symptoms include progressive exertional dyspnea and nonproductive cough. Inspiratory crackles may be heard on physical examination. Pulmonary function testing usually demonstrates a nonspecific spirometry or a mild restrictive pattern with a decrease in diffusion capacity. Similar to our case, a relatively normal or only mildly abnormal spirometry compared with the significant reduction in diffusing capacity is likely due to the nature of the disease, in which the accumulation of phospholipoproteinaceous material within the alveoli causes the gas exchange dysfunction more than the dynamic airflow abnormality. Chest radiography will demonstrate bilateral alveolar infiltrates out of proportion to the clinical presentation. Typical HRCT findings include ground-glass opacifications with superimposed interlobular septal thickening adjacent to normal lung parenchyma, colloquially referred to as 'crazy-paving' because of its resemblance to irregularly laid cobblestone paths (1). Despite the well-known association between 'crazy-paving' patterns and PAP, this radiographic finding is neither sensitive nor specific for the diagnosis of PAP. It can be observed in alveolar sarcoidosis, lipoid pneumonia, bronchioalveolar carcinoma, pneumocystis pneumonia, Nocardia infection, chronic eosinophilic pneumonia, acute interstitial pneumonia, acute respiratory distress syndrome or even hemorrhage (7)(8)(9). It must also be noted that PAP can present as interstitial, focal, nodular or ground-glass opacities, and even fibrosis; thus, it should not be ruled out if distinct alveolar infiltrates are not seen (1,10).
Adjunctive routine laboratory studies are rarely helpful in honing the diagnosis. However, if idiopathic PAP is suspected, serum anti-GM-CSF antibody titres or BAL fluid can be a helpful diagnostic tool (1); although its clinical utility needs to be validated in a large cohort study. Currently, the testing is not widely available and can be accomplished at specialized centres via sending a specifically packaged blood sample. Most commonly, bronchoscopy with BAL and transbronchial Hematoxylin and eosin stain, original magnification ×100. B Higher power inspection of the alveoli demonstrating thick, amorphous material with scattered pulmonary macrophages. Hematoxylin and eosin stain, original magnification ×400. Note: Grocott's methanamine silver staining was negative and ruled out pneumocystis pneumonia in the differential of 'crazy-paving' biopsy can be performed to confirm the diagnosis of PAP and rule out other conditions (1). Due to the the patchy nature of the disease, sampling error may result; therefore, if suspicion is high, video-assisted thoracoscopy or open lung biopsy should be performed. Typically, BAL reveals cloudy, milk-like fluid that when allowed to stand, separates into a translucent supernatant and thick sediment (1). Similar alveolar proteinaceous material may be observed in various inhalational exposures including silica, titanium or aluminum, and can also be seen in pneumocystis pneumonia, pulmonary nocardiosis and leukemia. Pathological differentiation of PAP from these other entities requires cytospin analysis, which usually reveals periodic acid-Schiff-positive, GMS stain-negative, eosinophilic, granular, acellular material with a few enlarged foamy macrophages (1). Once diagnosed, the underlying etiology of the PAP should be determined to guide management. Currently, the standard of care for the immediate treatment of any form of PAP is whole-lung lavage (WLL) under anesthesia (1). Unfortunately, congenital PAP responds poorly to WLL and, at this time, the only other option is lung transplantation (11). In cases of acquired PAP, definitive treatment rests on addressing the underlying disorder or avoiding the suspected environmental agent (1). Recently, studies have demonstrated that GM-CSF (inhalation or subcutaneous) can result in improvement in some patients with idiopathic PAP (12,13). Other options focus on reducing the amount of autoantibodies via B-cell depletion therapy (rituximab) or removal of autoantibodies (plasmapheresis); however, the exact role of these modalities remains to be defined (14,15). Furthermore, the use of lung transplantation for noncongenital PAP has not been clearly studied and recurrence after transplantation has been reported (16,17).

Figure 3) Categories, etiologies and pathophysiology of the various forms of pulmonary alveolar proteinosis (PAP). GM-CSF Granulocyte macrophage-colony stimulating factor
Our patient underwent WLL and his dyspnea and oxygen saturation improved. It is unknown whether his chronic exposure to cement and saw dust was directly associated with the development of PAP; however, he was advised to change his occupational environment and refrain from woodworking. On follow-up, the patient's dyspnea on exertion was no longer present and he continues to do well. The present case highlights the need to consider all differential diagnoses when alveolar infiltrates are seen and add PAP to the list of possibilities because the diagnosis can lead to the search for potential secondary etiologies and the treatment can result in significant clinical improvement.

Post-test
• What is the etiology of PAP?
○ The current state of research suggests that PAP results from a decrease in the clearance of phospholipoproteins from the alveolar space. Mechanistically, three various forms of PAP exist, but all of them uniformly result in macrophage dysfunction, whether it be from direct macrophage effect or indirectly via mutations or antibodies to the GM-CSF receptor resulting in accumulation of the proteinaceous material. • What are the various differential diagnoses associated with the 'crazy-paving' pattern that need to be considered and ruled out before making a diagnosis of PAP? ○ 'Crazy-paving' is the colloquial term for interlobular septal thickening with superimposed ground-glass opacities. The most common differential diagnosis that should be considered outside of PAP included bronchioalveolar carcinoma, Pneumocystis jirovecii infection, hemorrhage and, rarely, alveolar sarcoid. Appropriate diagnostic testing should ensue to rule out these etiologies, and definitive diagnosis of PAP should be made by demonstrating acellular, amorphous, eosinophilic, periodic acid-Schiff-positive material.